About Rx|X

Rx|X Advisory Services Founders, Dr. Madeline Wallack and Ms. Suzanne Herzog, have spent their careers, which span 20 years, in 340B and drug pricing compliance. 340B industry experts with experience working in a traditional compliance firm setting, Dr. Wallack and Ms. Herzog started Rx|X with a vision to create a firm that offered compliance services that were efficient, yet approachable.

Prior to launching Rx|X, Dr. Wallack and Ms. Herzog served for several years at the Office of Inspector General (OIG) for Health and Human Services (HHS). Later they pursued contractual work with Health Resources and Services Administration’s (HRSA) Office of Pharmacy Affairs. While at the OIG and HHS, both gained direct experience with statistics, audits, program evaluation, data collection methods, data analysis, technical writing, and project management. 

In 2010, Dr. Wallack and Ms. Herzog launched   Rx|X Advisory Services as an elevated means for 340B knowledge transfer to clients. Rx|X assists 340B entities with compliance, optimization, strategy, operations, and dispute resolution. While the firm specializes in advising large, complex health systems, Rx|X works with entities of all sizes. Due to their historical focus on 340B and the Medicaid Drug Rebate Program (MDRP), when founding Rx|X, Dr. Wallack and Ms. Herzog developed subject matter expertise specific to drug pricing programs. Today, Rx|x still relies on such expertise in most of its work.

Later that year, Dr. Wallack and Ms. Herzog served as expert witnesses for the Supreme Court case Santa Clara v Astra et al regarding overcharging of 340B entities. From 2011-2013, Rx|X worked with the American Pharmacists Association (APhA) as part of their contract with HRSA to run the Pharmacy Services Support Center (PSSC), now the call center/education/policy assistance service run by Apexus. The firm conducted research on policy and implementation questions and authored white papers. Furthermore, they ran the Covered Entity Peer-to-Peer Program, served as staff at 340B University, wrote standard response guides for the FAQs, and helped develop the HRSA audit process following the implementation of the Affordable Care Act (ACA).

In 2013, Rx|X oversaw HRSA’s audits and enforcement of the GPO prohibition. In 2016, Rx|X aided Apexus with the creation of the 340B Apexus Certified Expert (ACE) curriculum. In 2020, Rx|X served as ACE’s exclusive consultant helping to create the educational Update Module. Today, the firm audits for hundreds of clients, expertly preps entities for HRSA audits, and settles manufacturer disputes.

In 2024, the firm launched its inventory reconciliation tool, Avanti340B. The tool serves as a novel way to further support clients managing procurement and accumulation.